Faezeh Kheyri: Exploring the Future of Immunohematology with Artificial Intelligence
Faezeh Kheyri, Research Assistant at Iranian Blood Transfusion Organization, shared a post on LinkedIn:
“I’m pleased to share that I had the opportunity to present our poster at The 17th International and 23rd National Congress on Quality Improvement in Clinical Laboratories.
Our poster focused on the potential role of artificial intelligence in immunohematology laboratories, exploring how AI can contribute to improving laboratory processes, supporting data analysis, enhancing quality, and assisting laboratory professionals in making more informed decisions.
It was a valuable opportunity to exchange ideas, discuss this emerging field with colleagues and visitors, and explore the growing intersection of artificial intelligence and laboratory medicine.
I’m grateful for the opportunity to be part of such an inspiring scientific event and look forward to further exploring innovative technologies that can help shape the future of laboratory medicine.”
See more in the gallery.
Stay updated with Hemostasis Today.
-
Sep 6, 2026, 05:58Mohamed F Doheim: ‘Stroke as a Symphony’ – Rethinking Decision-Making in Acute Ischemic Stroke
-
Sep 6, 2026, 05:26Yousef Hindi: Unprovoked Left Renal Vein Thrombosis and Severe IDA – Long-Term Resolution and Dual-Energy CT Findings
-
Sep 6, 2026, 05:18Robert Brown: Standardizing Amniotic Fluid Embolism Diagnosis – SMFM and AFE Foundation Criteria
-
Sep 6, 2026, 04:45Mohammed Al Kanan: Early Identification of VTE Risk in Lung Cancer Patients
-
Sep 6, 2026, 04:38M. Ibrahim Siddique: Does Routine Triple Therapy Pay Off After Anterior STEMI?
-
Sep 6, 2026, 04:29Sandra Revill Tremulis: The Lp(a)HORIZON Topline Results Raise Important Questions Beyond Simply ‘Does Lowering Lp(a) Work?’
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX